Avac Event

AIDS Vaccine 2013

AIDS Vaccine 2013 took place from October 7–10 in Barcelona, Spain. AIDS Vaccine is the largest global scientific conference focused exclusively on AIDS vaccine research. Hosted annually by the Global HIV Vaccine Enterprise and local partners, AIDS Vaccine brings together the best and brightest scientific minds to exchange the latest research findings, explore new ideas, educate future leaders and engage a diverse community to help further research to develop a safe and effective HIV vaccine.

For the full program, click here . And, much of the conference is available via webcast here.

Jauhara Nanyondo

Jauhara has worked in the public health field for more than fifteen years, with a specific focus on biomedical prevention research. She has recently joined IAVI as the Associate Director for community engagement, and she spent the past decade at Makerere University Walter Reed Project (MUWRP), where she led their community outreach efforts.

Fellowship Focus
Jauhara developed an HIV prevention research training guide for the media in Uganda to help streamline content and scope. Her training guide filled an important gap, since at the time of her Fellowship—although there had been efforts to build media capacity to report effectively on new HIV prevention research—the content and scope of such workshops was limited.

In Their Own Words
Although we haven’t developed a safe and effective vaccine yet, we have come a long way in the past decade regarding HIV prevention and treatment options, with PrEP now available in many countries and microbicides possibly on the horizon. We’ve also had many breakthrough advances in vaccine research–including the RV144 result–that give us hope. We must keep at it, and every stakeholder must play their part.

hivresourcetracking.org

The most up-to-date and comprehensive field-wide estimates for HIV prevention and R&D globally.

In its 16th annual report, the Resource Tracking for HIV Prevention Research & Development Working Group documents research and development spending for the calendar year 2020 and analyzes funding trends spanning twenty years.

Pregnant and Lactating People (PLP) in Ongoing HIV Prevention Trials

Current trends for investment in HIV prevention R&D by technology

Status Updates on Ongoing and Planned HIV Prevention Trials

The world is grappling with the far-reaching impacts of the COVID-19 pandemic and the HIV prevention field is no different. Most trials investigating new biomedical HIV prevention products have paused, citing concerns for the safety of trial participants and the study teams.

How COVID-19 is impacting research varies by trial and site, and efforts are ongoing to minimize impact on trial timelines and data. AVAC will continue to monitor developments—watch this space.

Ongoing Studies for the Treatment and Prevention of the COVID-19 Virus

This table is a work in progress, as this is an incredibly dynamic landscape. Over the past month, the scientific community has accelerated development of COVID-19 diagnostics, therapeutics and a potential vaccine. This document also links to a number of resources available to track these developments.

In addition, a collaborative project of the COVID-19 Working Group NY, the PrEP4All Collaboration and Treatment Action Group offers concise overviews and analyses of key research areas.

COVID-19 Resources for Advocates

This document is to help advocates with links to the latest information about COVID-19, including information on its prevention, transmission, relationship to HIV and research that’s underway. Many of the links below are constantly updated so please click through for the latest.

AIDS Vaccines by the Numbers: Trials, discoveries, money and more

We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward. The graphics below represent key facts about the AIDS vaccine field.

This Week! Webinars on Mosaico Study and Trans Manifesto

AVAC has two webinars this week you won’t want to miss!

Tomorrow, January 25, at 9 AM PST/12 PM EST/6 PM CET, AVAC and HIV Vaccine Trials Network (HVTN) will host a webinar called Where Are We and Next Steps. As the field explores what the ending of the Mosaico study means for vaccine research, we’ll be joined by study investigators and community representatives to further interrogate what a post Mosaico trial looks like, key takeaways from the study, and ways to remain hopeful for an HIV vaccine. Register here.

On Thursday, January 26 at 10:00 AM EST / 3:00 PM GMT, The Choice Agenda is hosting its first webinar of 2023, Trans Inclusion: Charting HIV Research into the Future: A Manifesto and Scorecard for Advocates and Researchers. The webinar will explore why trans-inclusive and trans-centered research is not only the right the thing to do for equity in the global response, but also necessary to end the epidemic. Register here and join our growing community of HIV prevention advocates (Over 1,000 and counting!) with The Choice Agenda listserv.

We look forward to virtually connecting soon!

Stay up-to-date!